Physician profile
Wondiful A Colbert
NPI 1548248636
$3,200.12
in general payments reported to CMS, 2019-2025
28 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $178 · 2021: $382 · 2022: $650 · 2023: $835 · 2024: $522 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,746.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $808.43 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $316.26 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $266.34 | 2022-2025 | |
| Abbvie INC. | $201.77 | 2021-2024 | Linzess, Viberzi, Creon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.36 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $160.07 | 2019-2025 | Breztri |
| Amarin Pharma, INC. | $157.41 | 2019-2021 | |
| Amgen INC. | $129.13 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $124.65 | 2019-2024 | Gardasil 9, Gardasil, M-M-R II |
| Glaxosmithkline, LLC. | $83.76 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $81.80 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $80.35 | 2022-2023 | |
| Dexcom, INC. | $78.46 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $70.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.03 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $59.79 | 2024-2025 | Veozah |
| Eisai INC. | $42.24 | 2020-2021 | |
| Shield Therapeutics INC | $39.30 | 2023-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $38.87 | 2021 | |
| Dynavax Technologies Corporation | $28.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $26.62 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $25.72 | 2021 | |
| Abbott Laboratories | $24.40 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $22.67 | 2023 | Closurefast |
| Convatec INC. | $21.79 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.71 | 2022 | |
| Stryker Corporation | $15.70 | 2019 | |
| Mylan Specialty L.P. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wondiful Colbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.